Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity (2015) 1.34

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood (2016) 0.94

T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine (2015) 0.92

IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection. Mucosal Immunol (2016) 0.87

CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol (2016) 0.86

Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol (2015) 0.85

Inducing and Administering Tregs to Treat Human Disease. Front Immunol (2016) 0.84

Innate lymphoid cell function in the context of adaptive immunity. Nat Immunol (2016) 0.82

Regulation of metabolic health and adipose tissue function by group 2 innate lymphoid cells. Eur J Immunol (2016) 0.76

Therapeutic window of interleukin-2 for autoimmune diseases. Diabetes (2015) 0.76

T Regulatory Cells Support Plasma Cell Populations in the Bone Marrow. Cell Rep (2017) 0.75

Heightened Immune Activation in Fetuses with Gastroschisis May Be Blocked by Targeting IL-5. J Immunol (2016) 0.75

Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy Asthma Clin Immunol (2017) 0.75

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature (2010) 10.34

Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature (2009) 9.71

Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A (2010) 6.78

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08

Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39

The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97

In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med (2009) 3.78

The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity (2012) 3.65

Innate lymphoid cells--how did we miss them? Nat Rev Immunol (2013) 3.62

Type 2 innate lymphoid cells control eosinophil homeostasis. Nature (2013) 3.20

Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med (2013) 2.79

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol (2013) 1.92

Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol (2013) 1.91

Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood (1995) 0.98

IL-2 therapy in type 1 diabetes: "Trials" and tribulations. Clin Immunol (2013) 0.97

Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood (1991) 0.86

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol (2014) 0.84

Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes (2013) 0.84

Low-dose subcutaneous interleukin-2 in patients with minimal residual lymphoid neoplasm disease. Eur J Haematol (1999) 0.78